Statement of Renovaro Inc - Seite 2

Dr. Coen van Kalken, MD PhD said, “We were one of the original investors in the technology GEDi Cube acquired as a holding company. I have seen the remarkable advancement of the underlying, award-winning deep machine learning from its origins in Fintech to its current applications in the biomedical space. As a clinician, scientist and entrepreneur for more than 3 decades, I became so captivated by the accelerated progress, in particular in the past year, it was not a difficult decision to accept the offer to lead GEDiCube, now RenovaroCube. In addition to our own technology, we are rapidly expanding our network of current and potential partners. We are fortunate that Dr. Henk Vietor, MD PhD, a well-known and respected clinical geneticist, researcher and health care entrepreneur has joined as CMO. We are both convinced of RenovaroCube’s lifesaving commercial potential and the prospect of products in the marketplace already this year.”

The Board and Management remain confident in the future of the Company and believe people will see these baseless attacks for what they are.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K and its definitive proxy statement related to the acquisition of GEDi Cube Intl Ltd. filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

Contact Information:

[e-mail]

Source: Renovaro Bioscience